Astellas Pharma ALPMY

OTC: ALPMY | ISIN: US04623U1025 3/07/2025

9,600 USD (-0,21%)

(-0,21%) 3/07/2025

Grafiek Astellas Pharma

Grafiek Astellas Pharma

1 dag1d -0,21%
1 week1w -1,44%
1 maand1m -0,62%
3 maanden3m 7,74%
6 maanden6m -0,72%
1 jaar1j -4,00%
5 jaar5j -41,78%

Astellas Pharma in het nieuws

Toon enkel gratis nieuws

7 mei 2025 · Notice of Nominees for Directors · Persbericht

1 mei 2025 · Astellas to Present New Data in Geographic Atrophy at Upcoming Ophthalmology Annual Congresses · Persbericht

6 maart 2025 · Astellas and YASKAWA Agree to Establish a Joint Venture Focused on Cell Therapy Manufacturing · Persbericht

11 september 2024 · Astellas Presents Scientific Progress in Advanced and Hard-to-Treat Cancers at ESMO 2024 · Persbericht

5 september 2024 · Astellas Unveils New Life Sciences Center in Cambridge, Massachusetts to Accelerate the Discovery of Breakthrough Therapies · Persbericht

4 september 2024 · Astellas to Present VEOZAH™ (fezolinetant) Data at 2024 Annual Meeting of The Menopause Society · Persbericht

28 augustus 2024 · European Commission Approves Astellas' PADCEV™ (enfortumab vedotin) in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Urothelial Cancer · Persbericht

27 augustus 2024 · Astellas Initiates Phase 3 Clinical Study of Fezolinetant for VMS in Women with Breast Cancer Receiving Adjuvant Endocrine Therapy · Persbericht

20 augustus 2024 · China's National Medical Products Administration (NMPA) Approves PADCEV™ (enfortumab vedotin) for Treatment of Locally Advanced or Metastatic Urothelial Cancer · Persbericht

26 juli 2024 · Astellas Receives Positive CHMP Opinion for Zolbetuximab in Combination with Chemotherapy for Treatment of Advanced Gastric and Gastroesophageal Junction Cancer · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe